Metabolomics approaches in pancreatic adenocarcinoma: Tumor metabolism profiling predicts clinical outcome of patients

Simple item page
dc.citation.epage16en_US
dc.citation.issueNumber56en_US
dc.citation.spage1en_US
dc.citation.volumeNumber15en_US
dc.contributor.authorBattini, S.en_US
dc.contributor.authorFaitot, F.en_US
dc.contributor.authorImperiale, A.en_US
dc.contributor.authorCicek, A. E.en_US
dc.contributor.authorHeimburger, C.en_US
dc.contributor.authorAverous, G.en_US
dc.contributor.authorBachellier, P.en_US
dc.contributor.authorNamer, I. J.en_US
dc.date.accessioned2018-04-12T11:01:13Z
dc.date.available2018-04-12T11:01:13Z
dc.date.issued2017en_US
dc.departmentDepartment of Computer Engineeringen_US
dc.description.abstractPancreatic adenocarcinomas (PAs) have very poor prognoses even when surgery is possible. Currently, there are no tissular biomarkers to predict long-term survival in patients with PA. The aims of this study were to (1) describe the metabolome of pancreatic parenchyma (PP) and PA, (2) determine the impact of neoadjuvant chemotherapy on PP and PA, and (3) find tissue metabolic biomarkers associated with long-term survivors, using metabolomics analysis. Methods: 1H high-resolution magic angle spinning (HRMAS) nuclear magnetic resonance (NMR) spectroscopy using intact tissues was applied to analyze metabolites in PP tissue samples (n = 17) and intact tumor samples (n = 106), obtained from 106 patients undergoing surgical resection for PA. Results: An orthogonal partial least square-discriminant analysis (OPLS-DA) showed a clear distinction between PP and PA. Higher concentrations of myo-inositol and glycerol were shown in PP, whereas higher levels of glucose, ascorbate, ethanolamine, lactate, and taurine were revealed in PA. Among those metabolites, one of them was particularly obvious in the distinction between long-term and short-term survivors. A high ethanolamine level was associated with worse survival. The impact of neoadjuvant chemotherapy was higher on PA than on PP. Conclusions: This study shows that HRMAS NMR spectroscopy using intact tissue provides important and solid information in the characterization of PA. Metabolomics profiling can also predict long-term survival: the assessment of ethanolamine concentration can be clinically relevant as a single metabolic biomarker. This information can be obtained in 20 min, during surgery, to distinguish long-term from short-term survival. © 2017 The Author(s).en_US
dc.description.provenanceMade available in DSpace on 2018-04-12T11:01:13Z (GMT). No. of bitstreams: 1 bilkent-research-paper.pdf: 179475 bytes, checksum: ea0bedeb05ac9ccfb983c327e155f0c2 (MD5) Previous issue date: 2017en
dc.identifier.doi10.1186/s12916-017-0810-zen_US
dc.identifier.eissn1741-7015
dc.identifier.urihttp://hdl.handle.net/11693/37046
dc.language.isoEnglishen_US
dc.publisherBioMed Central Ltd.en_US
dc.relation.isversionofhttp://dx.doi.org/10.1186/s12916-017-0810-zen_US
dc.source.titleBMC Medicineen_US
dc.subjectBiomarkeren_US
dc.subjectHRMASen_US
dc.subjectLong-term survivalen_US
dc.subjectMetabolomicsen_US
dc.subjectNMRen_US
dc.subjectPancreatic adenocarcinomaen_US
dc.titleMetabolomics approaches in pancreatic adenocarcinoma: Tumor metabolism profiling predicts clinical outcome of patientsen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Metabolomics approaches in pancreatic.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format
Description:
Full printable version
Download

Collections

Scholarly Publications - Computer Engineering